Download PDF
Thromb Haemost 1995; 74(05): 1225-1230
DOI: 10.1055/s-0038-1649916
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Increased Thromboxane Biosynthesis in Essential Thrombocythemia

Bianca Rocca
1   The Department of Medicine, Catholic University School of Medicine, Rome, Italy
,
Giovanni Ciabattoni
2   The Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
,
Raffaele Tartaglione
1   The Department of Medicine, Catholic University School of Medicine, Rome, Italy
,
Sergio Cortelazzo
3   The Division of Hematology, Bergamo’;s Civil Hospital, Bergamo, Italy
,
Tiziano Barbui
3   The Division of Hematology, Bergamo’;s Civil Hospital, Bergamo, Italy
,
Carlo Patrono
4   The Department of Pharmacology, University of Chieti “G. D’Annunzio” School of Medicine, Chieti, Italy
,
Raffaele Landolfi
1   The Department of Medicine, Catholic University School of Medicine, Rome, Italy
› Author Affiliations
Further Information

Publication History

Received 20 February 1995

Accepted 12 July 1995

Publication Date:
10 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In order to investigate the in vivo thromboxane (TX) biosynthesis in essential thromboeythemia (ET), we measured the urinary exeretion of the major enzymatic metabolites of TXB2, 11-dehydro-TXB2 and 2,3-dinor-TXB2 in 40 ET patients as well as in 26 gender- and age-matched controls. Urinary 11-dehydro-TXB2 was significantly higher (p <0.001) in thrombocythemic patients (4,063 ± 3,408 pg/mg creatinine; mean ± SD) than in controls (504 ± 267 pg/mg creatinine), with 34 patients (85%) having 11-dehydro-TXB2 >2 SD above the control mean. Patients with platelet number <1,000 × 109/1 (n = 25) had significantly higher (p <0.05) 11 -dehydro-TXB2 excretion than patients with higher platelet count (4,765 ± 3,870 pg/mg creatinine, n = 25, versus 2,279 ± 1,874 pg/mg creatinine, n = 15). Average excretion values of patients aging >55 was significantly higher than in the younger group (4,784 ± 3,948 pg/mg creatinine, n = 24, versus 2,405 ± 1,885 pg/mg creatinine, n = 16, p <0.05). Low-dose aspirin (50 mg/d for 7 days) largely suppressed 11-dehydro-TXB2 excretion in 7 thrombocythemic patients, thus suggesting that platelets were the main source of enhanced TXA2 biosynthesis. The platelet count-corrected 11-dehydro-TXB2 excretion was positively correlated with age (r = 0.325, n = 40, p <0.05) and inversely correlated with platelet count (r = -0.381, n = 40, p <0.05). In addition 11 out of 13 (85%) patients having increased count-corrected 11-dehydro-TXB2 excretion, belonged to the subgroup with age >55 and platelet count <1,000 × 1099/1. We conclude that in essential thrombocythemia: 1) enhanced 11-dehydro-TXB2 excretion largely reflects platelet activation in vivo;2) age as well as platelet count appear to influence the determinants of platelet activation in this setting, and can help in assessing the thrombotic risk and therapeutic strategy in individual patients.

 

  • References

  • 1 Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-12
    PubMedGoogle Scholar
  • 2 Mitus J, Schafer AI. Thrombocytosis and thrombocythemia. Hematol/Oncol Clin North Am 1990; 4: 157-178
    CrossrefPubMedGoogle Scholar
  • 3 Schafer AI. Essential thrombocythemia. Progr Haemost Thromb 1991; 10: 69-96
    PubMedGoogle Scholar
  • 4 Landolfi R, Ciabattoni G, Patrignani P, Castellana M, Pogliani E, Bizzi B, Patrono C. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80: 1965-1971
    CrossrefPubMedGoogle Scholar
  • 5 van Genderen P, Michiels J. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Press Med 1994; 23: 73-77
    PubMedGoogle Scholar
  • 6 Fenaux P, Simon M, Cauliere MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549-556
    CrossrefPubMedGoogle Scholar
  • 7 Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R. Essential thrombocythemias. Clinical evolutionary and biological data Cancer 1986; 58: 2240-2247
    PubMedGoogle Scholar
  • 8 Randi M, Stocco F, Rossi C, Tison T, Girolami A. Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients. J Med 1991; 22: 213-223
    PubMedGoogle Scholar
  • 9 Kessler C, Klein H, Havlik R. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 1982; 50: 157-167
    CrossrefPubMedGoogle Scholar
  • 10 Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients Ann Hematol 1991; 63: 101-106
    CrossrefPubMedGoogle Scholar
  • 11 Tura S. Le trombocitémie. Haematologica 1979; 64: 179-218
    PubMedGoogle Scholar
  • 12 Cortelazzo S, Viero P, Finazzi G, D’ Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocytemia. J Clin Oncol 1990; 8: 556-599
    CrossrefPubMedGoogle Scholar
  • 13 Hehlmann R, Jahn M, Baumann B, Köpcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases Cancer 1988; 61: 2487-2496
    CrossrefPubMedGoogle Scholar
  • 14 Lahuierta-Palaeios J, Bomslein R, Fernandcz-Debora F, Guliémiz-Rivas E, Orliz M, Larregla S, Calandre L, Monlcro-Caslillo J. Controlled and uncontrolled thrombocytosis. Its clinical role inessential thrombocythemia Cancer 1988; 61: 1207-1212
    CrossrefPubMedGoogle Scholar
  • 15 Colombi M, Radaelli F, Zocehi L, Maiolo A. Thrombotic and hemorrhagic complications in essential thrombocythemia. Cancer 1991; 67: 2926-2930
    CrossrefPubMedGoogle Scholar
  • 16 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castmeei G, De Salvo A, Satta MA, Peskar BA. Low-dose aspirin and inhibition of thromboxane B, production in healthy subjects. Thromb Res 1980; 17: 317-327
    CrossrefPubMedGoogle Scholar
  • 17 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. min Invest 1982; 69: 1366-1372
    PubMedGoogle Scholar
  • 18 Roberts IJ, Sweetman BI, Oates JA. Metabolism of thromboxane B, in man. Identification of twenty urinary metabolites J Biol Chcm 1981; 256: 8384-8393
    PubMedGoogle Scholar
  • 19 Ciabattoni G, Pugliese F, Davì G, Picrucci A, Simonctti BM, Patrono C. Fractional conversion of thromboxane B, to urinary 11-dehydro thromboxane B2in man. Biochim Biophys Aeta 1989; 992: 66-70
    PubMedGoogle Scholar
  • 20 Ciabattoni Cl, Maclouf J, Catella F, FitzGerald GA, Patrono C. Radio immunoassay of I l-dehydro-thromboxanc B2in human plasma and urine. Biochim Biophys Acta 1987; 918: 293-297
    CrossrefPubMedGoogle Scholar
  • 21 Patrono C, Ciabattoni G, Rcmuzzi G, Gotti E, Bombardieri S, Di Munno O, Tartarelli GA, Simonctti BM, Picrucci A. Functional significance of renal prostacyclin and thromboxane A2production in patients with systemic lupus erythematosus. J Clin Invest 1985; 76: 1011-1018
    CrossrefPubMedGoogle Scholar
  • 22 Alessandrini P, Avogaro P, Bittolo Bon G, Patrignani P, Patrono C. Physiologic variables affecting thromboxane B2production in human whole blood. Thromb Res 1985; 37: 1-8
    CrossrefPubMedGoogle Scholar
  • 23 FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-1177
    CrossrefPubMedGoogle Scholar
  • 24 Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989
    CrossrefPubMedGoogle Scholar
  • 25 Vejar M, Fragasso G, Hackett D, Lipkin D, Maseri A, Bom GV R, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemostas 1990; 6: 163-168
    PubMedGoogle Scholar
  • 26 Koudstaal P, Ciabattoni G, van Gijn J, Nieuwenhuis HK, de Groot P, Sixma JJ, Patrono C. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke 1993; 24: 219-223
    CrossrefPubMedGoogle Scholar
  • 27 Di Minno G, Davì G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, Strisciuglio P, Andria G, Patrono C, Mancini M. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. J Clin Invest 1993; 92: 1400-1406
    CrossrefPubMedGoogle Scholar
  • 28 Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-1774
    CrossrefPubMedGoogle Scholar
  • 29 Davì G, Averna M, Catalano I, Barbagallo C, Ganci A, Notarbartolo A, Ciabattoni G, Patrono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 1992; 85: 1792-1798
    CrossrefPubMedGoogle Scholar
  • 30 Burch J, Stanford N, Majerus P. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-9
    CrossrefPubMedGoogle Scholar
  • 31 Reilly I, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186
    PubMedGoogle Scholar
  • 32 Han ZC, Bellucci S, Bodevin E, Shen ZX, Caen JP. In vivo inhibition of megakaryocyte and platelet production by platelet factor 4 in mice. C R Acad Sci 1991; 313: 553-558
    PubMedGoogle Scholar
  • 33 Preston FE, Emmanuel IG, Winfield DA, Malia RG. Essential thrombocythaemia and peripheral gangrene. BMJ 1974; 3: 548-552
    CrossrefPubMedGoogle Scholar
  • 34 Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 1989; 320: 915-924
    CrossrefPubMedGoogle Scholar
  • 35 Iuliano L, Pedersen JZ, Praticò D, Rotilio G, Violi F. Role of hydroxyl radicals in the activation of human platelets. Eur J Biochem 1994; 221: 695-704
    CrossrefPubMedGoogle Scholar
  • 36 Mcintyre K, Hoagland H, Silverstein M, Petit R, Hoagland HC, Silverstein MN, Petitt RM. Essential thrombocythemia in young adults. Mayo Clin Proc 1991; 66: 149-154
    CrossrefPubMedGoogle Scholar
  • 37 Randi ML, Fabris F, Rossi C, Tison T, Barbone E, Girolami A. Sex and age as prognostic factors in essential thrombocythemia. Haematologica 1992; 77: 402-404
    PubMedGoogle Scholar
  • 38 Randi ML, Fabris F, Girolami A. Thrombocytosis in young people:evaluation of 57 cases diagnosed before the age of 40. Blut 1990; 60: 233-237
    CrossrefPubMedGoogle Scholar
  • 39 Mitus AJ, Barbui T, Shulman N, Rosenthal D, Viero P, Cortelazzo S, Schafer AI. Hemostatic complications in young patients with essential thrombocythemia. Am J Med 1990; 88: 371-375
    CrossrefPubMedGoogle Scholar
  • 40 Millard FE, Hunter CS, Anderson M, Edelman MJ, Kosty MP, Luiken GA, Marino GG. Clinical manifestations of essential thrombocythemia in young adults. Am J Hematol 1990; 33: 27-31
    CrossrefPubMedGoogle Scholar
  • 41 Barbui T, Buelli M, Cortelazzo S, Viero P. Aspirin and risk of bleeding in patients with thrombocythemia. Am J Med 1987; 83: 265-266
    CrossrefPubMedGoogle Scholar
  • 42 Vreeken J, van Aken WG. Spontaneous aggregation of blood platelets as a cause of idiopathic and recurrent painful toes and fingers. Lancet 1971; 2: 1394-1397
    PubMedGoogle Scholar
  • 43 Michiels JJ, ten Cate FW J, Vuzevski VD, Abels J. Histopathology of erythromelalgia in thrombocythaemia. Histopathology 1984; 8: 669-678
    CrossrefPubMedGoogle Scholar
  • 44 Michiels J, Abels J, Steketee J, van Vliet HH D M, Vuzevski KD. Erythromelalgia caused by platelet-mediated arteriolarinflammation and thrombosis in thrombocythemia. Ann Intern Med 1985; 102: 466-471
    CrossrefPubMedGoogle Scholar
  • 45 Michiels JJ, van Joost TH. Erythromelalgia and thrombocythemia. A causal relation J Amer Acad Dermatol 1990; 22: 101-111
    CrossrefPubMedGoogle Scholar
  • 46 Michiels J, Zijlstra F. Prostaglandin cyclooxygenase products but not thromboxane A2are involved in the pathogenesis of erythromelalgia in thrombocythaemia. Mediators of Inflammation 1993; 2: 385-389
    CrossrefPubMedGoogle Scholar
  • 47 Drenth JP H, Michiels JJ. Erythromelalgia and erythermalgia: diagnostic differentiation. Int J Dermatol 1994; 33: 393-397
    CrossrefPubMedGoogle Scholar
  • 48 Michiels JJ, Koudstaal PJ, Mulder AH, vanVliet HH D M. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993; 43: 1101-1110
    PubMedGoogle Scholar
  • 49 Jabaily J, Hand HJ, Lazio J, Massey EW, Faguet GB, Briere J, Landaw SA, Pisciotta AV. Neurologic manifestations of essential thrombocythemia. Ann Intern Med 1983; 99: 513-518
    CrossrefPubMedGoogle Scholar
  • 50 Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294
    CrossrefPubMedGoogle Scholar